Cilengitide targets pediatric glioma and neuroblastoma cells through cell detachment and anoikis induction.

Abstract:

:The prognosis of children with high-grade glioma or high-risk neuroblastoma remains poor. Cilengitide is a selective antagonist of αvβ3 and αvβ5 integrins, which are involved in tumor growth and development of metastasis. We have evaluated the effects of cilengitide on pediatric glioma and neuroblastoma cell lines for the first time. Expression levels of αvβ3 and αvβ5 were determined by flow cytometry in three neuroblastoma and five pediatric glioma cell lines compared with adult U87-MG before and after irradiation. Cell detachment, cytotoxicity, and cell growth under nonadhesive conditions were measured using the MTS assay. Cell death and apoptosis were assessed by annexin-V/propidium iodide staining. The varying αvβ3 and αvβ5 expression levels were unrelated to tumor grade. Irrespective of the αvβ5 expression level, the pediatric cells expressing αvβ3 were dose dependently sensitive to cilengitide. UW479 cells expressed only αvβ5 integrin and were not sensitive to cilengitide, suggesting that cilengitide's action largely depends on αvβ3 inhibition. Cell detachment resulted in a higher cytotoxicity in pediatric glioma compared with U87-MG cells, which seem able to grow despite the significant cilengitide-induced cell detachment. Growth kinetics on polyHEMA showed that only pediatric glioma cells were sensitive to anoikis and so died after cilengitide-induced detachment. Furthermore, irradiation of glioma cells increased αvβ3 expression slightly but not cilengitide sensitivity. Cilengitide's action on glioma and neuroblastoma cells appears to be dependent on αvβ3 expression and sensitivity to anoikis. Cilengitide is able to target pediatric glioma and neuroblastoma cells in vitro directly and efficiently. Tumor context could validate these promising observations.

journal_name

Anticancer Drugs

journal_title

Anti-cancer drugs

authors

Leblond P,Dewitte A,Le Tinier F,Bal-Mahieu C,Baroncini M,Sarrazin T,Lartigau E,Lansiaux A,Meignan S

doi

10.1097/CAD.0b013e328362edc5

subject

Has Abstract

pub_date

2013-09-01 00:00:00

pages

818-25

issue

8

eissn

0959-4973

issn

1473-5741

journal_volume

24

pub_type

杂志文章
  • Trastuzumab in combination with paclitaxel enhances antitumor activity by promoting apoptosis in human epidermal growth factor receptor 2-positive trastuzumab-resistant gastric cancer xenograft models.

    abstract::Trastuzumab, a humanized anti-human epidermal growth factor receptor 2 antibody drug, is the first-line therapy for human epidermal growth factor receptor 2-positive breast and gastric cancer. For breast cancer, the benefit of continuous treatment with trastuzumab after it becomes refractory to first-line therapy has ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000853

    authors: Shu S,Yamashita-Kashima Y,Yanagisawa M,Nakanishi H,Kodera Y,Harada N,Yoshimura Y

    更新日期:2020-03-01 00:00:00

  • Interleukin-2 treatment effect on imatinib pharmacokinetic, P-gp and BCRP expression in mice.

    abstract::The aim of this study was to investigate the effect that recombinant interleukin-2 (rIL-2) (0.16 MUI/injection) had on the pharmacokinetics of imatinib (IM) in plasma. In this study, IM was given orally to mice at a dose of 150 mg/kg once a day for 11 days (from day 1 to 11) either alone or in combination with intrape...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e3283349913

    authors: Hosten B,Abbara C,Cibert M,Petit B,Farinotti R,Gonin P,Bonhomme-Faivre L

    更新日期:2010-02-01 00:00:00

  • Control of nausea and vomiting by Navoban (tropisetron) in 131 children receiving cytotoxic chemotherapy.

    abstract::One hundred and thirty-one children with a median age of 5 years were administered Navoban (tropisetron), a selective antagonist of the serotonin receptor (5-HT3), dosed once daily at 0.2 mg/kg (with a maximum of 5 mg daily) in a study aimed at evaluating the prevention of nausea and vomiting induced by anti-cancer ch...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1097/00001813-199502001-00003

    authors: Benoit Y,Hulstaert F,Vermylen C,Sariban E,Hoyoux C,Uyttebroeck A,Otten J,Laureys G,De Kerpel I,Nortier D

    更新日期:1995-02-01 00:00:00

  • A functionalized poly(amidoamine) nanocarrier-loading 5-fluorouracil: pH-responsive drug release and enhanced anticancer effect.

    abstract::A functionalized poly(amidoamine) (PAMAM) nanocarrier was designed and prepared to deliver anticancer drugs. The nanocarrier is a copolymer with a core-shell structure with 3.0 G PAMAM as the core and sequentially conjugated poly(2-(N,N-diethylamino)ethyl methacrylate) (pDEA) and methoxy-poly(ethylene glycol) 2000 (mP...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e32835920fa

    authors: Du L,Jin Y,Yang J,Wang S,Wang X

    更新日期:2013-02-01 00:00:00

  • Effect of dolastatin 10 on human non-Hodgkin's lymphoma cell lines.

    abstract::It is crucial to incorporate new and more potent antineoplastic agents in treating non-Hodgkin's lymphoma since standard chemotherapy fails to cause a significant increase in the survival rate. A potential chemotherapeutic agent is dolastatin 10; hence, the objective of our study is to investigate the effect of the an...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199605000-00016

    authors: Maki A,Mohammad R,Raza S,Saleh M,Govindaraju KD,Pettit GR,al-Katib A

    更新日期:1996-05-01 00:00:00

  • Chemotherapy for recurrent/metastatic head and neck cancers.

    abstract::Chemotherapy is the only option of treatment for most patients presenting with a recurrent and/or metastatic head and neck squamous cell carcinoma. The triple association of cisplatin, 5-fluorouracile, and cetuximab is still the current standard for fit patients. Other schemes are currently being compared with this pr...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/CAD.0000000000000473

    authors: Karabajakian A,Toussaint P,Neidhardt EM,Paulus V,Saintigny P,Fayette J

    更新日期:2017-04-01 00:00:00

  • Tamoxifen and epigallocatechin gallate are synergistically cytotoxic to MDA-MB-231 human breast cancer cells.

    abstract::High concentrations of specific catechins [epigallocatechin gallate (EGCG), epigallocatechin (EGC) and epicatechin gallate (ECG)] inhibit the proliferation of many different cancer cell lines. The aim of this work was to determine if low concentrations of catechins with and without 4-hydroxytamoxifen (4-OHT) co-treatm...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200410000-00010

    authors: Chisholm K,Bray BJ,Rosengren RJ

    更新日期:2004-10-01 00:00:00

  • Docetaxel in squamous cell cancer of the head and neck.

    abstract::Single-agent docetaxel induces a response in 21-42% of patients with recurrent squamous cell cancer of the head and neck (SCCHN). When used in combination with 5-fluorouracil (5-FU), response rates (RRs) of between 24 and 27% have been reported. In contrast, in combination with cisplatin, docetaxel has achieved a RR o...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:

    authors: Posner MR

    更新日期:2001-02-01 00:00:00

  • Taxol and vinorelbine: a new active combination for disseminated malignant melanoma.

    abstract::We evaluated the activity and toxicity of two sequences of taxol combined with vinorelbine in disseminated malignant melanoma, metastatic beyond regional lymph nodes. Fifteen previously untreated patients, nine males and six females (median age 56 years), were enlisted between May 1994 and February 1995. Eight patient...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章

    doi:10.1097/00001813-199602000-00003

    authors: Retsas S,Mohith A,Mackenzie H

    更新日期:1996-02-01 00:00:00

  • Vitamin C suppresses the cisplatin toxicity on blood platelets.

    abstract::The effects of vitamin C on the oxidative stress in blood platelets induced by cisplatin were studied. In the presence of vitamin C we measured in blood platelets the production of thiobarbituric acid reactive substances (TBARS), the generation of superoxide radicals (O2*-), other reactive oxygen species (H2O2, single...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200007000-00010

    authors: Olas B,Wachowicz B,Buczyński A

    更新日期:2000-07-01 00:00:00

  • The marine alkaloid naamidine A promotes caspase-dependent apoptosis in tumor cells.

    abstract::Apoptosis is important for normal development and removal of damaged cells. Evasion of apoptosis by cancer cells is one of the key characteristics of many tumor types. Thus, discovering agents that promote apoptosis in tumor cells could have great therapeutic value. Marine natural products have demonstrated great pote...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e32832ae55f

    authors: LaBarbera DV,Modzelewska K,Glazar AI,Gray PD,Kaur M,Liu T,Grossman D,Harper MK,Kuwada SK,Moghal N,Ireland CM

    更新日期:2009-07-01 00:00:00

  • Blockade of GLUT1 by WZB117 resensitizes breast cancer cells to adriamycin.

    abstract::The tolerance to adriamycin of cancer as a common and stubborn obstacle occurred during curing breast cancer patients needs to be overcome. In the present study, we explored whether inhibiting the glucose transporter 1 (GLUT1) could restore the activity of adriamycin in breast cancer cell line MCF-7 resistant to adria...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000529

    authors: Chen Q,Meng YQ,Xu XF,Gu J

    更新日期:2017-09-01 00:00:00

  • Dose-dense primary systemic chemotherapy with gemcitabine plus epirubicin sequentially followed by docetaxel for early breast cancer: final results of a phase I/II trial.

    abstract::We recruited 50 patients with T2-4 N0-2 M0 primary breast cancer into a phase I/II study to define the maximum tolerated dose (MTD), efficacy and tolerability of preoperative gemcitabine (1250 mg/m fixed dose) plus epirubicin (doses escalated from 90 mg/m) for 5 cycles followed by 4 cycles of docetaxel (scheduled fixe...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章

    doi:10.1097/01.cad.0000176508.73090.fb

    authors: Schneeweiss A,Schuetz F,Rudlowski C,Hahn M,Lauschner I,Sinn HP,von Fournier D,Sohn C

    更新日期:2005-10-01 00:00:00

  • A phase I study of paclitaxel, estramustine phosphate and vinorelbine (Pacl-E-Vin) in advanced malignancies: triple tubulin targeting.

    abstract::Anti-tubulin couplets have activity in hormone-resistant prostate cancer. This study was designed to define the dose-limiting toxicity (DLT) and recommended phase II dose (RPTD) of the unique triplet combination of paclitaxel, estramustine phosphate (EMP) and vinorelbine (Pacl-E-Vin). Patients with advanced malignanci...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章

    doi:10.1097/00001813-200301000-00009

    authors: Sewak S,Chachoua A,Hamilton A,Taneja S,Lee J,Utate M,Sorich J,Muggia FM

    更新日期:2003-01-01 00:00:00

  • Gemcitabine plus cisplatin chemotherapy with concurrent para-toluenesulfonamide local injection therapy for peripherally advanced nonsmall cell lung cancer larger than 3 cm in the greatest dimension.

    abstract::Para-toluenesulfonamide (PTS), active ingredient being PTS, is a new anticancer drug applied through local intratumoral injection. The aim of this phase II clinical trial was to investigate the response and toxicity of standard gemcitabine (GEM) plus cisplatin (CIS) chemotherapy with concurrent intratumoral injection ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e32832fe48f

    authors: He J,Ying W,Yang H,Xu X,Shao W,Guan Y,Jiang M,Wu Y,Zhong B,Wang D,Tucker S,Zhong N

    更新日期:2009-10-01 00:00:00

  • Survival response of a human glioma cell line to hyperthermia associated with rhein.

    abstract::The effect of association of hyperthermia with the anti-inflammatory drug rhein (RH), 4,5-dihydroxyanthraquinone-2-carboxylic acid, on the clonogenic activity of human glioma cells has been examined. RH inhibits neoplastic growth mainly through an ATP depletion, but thermal cell killing is not mediated by the drug-ind...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199208000-00015

    authors: Floridi A,Gentile PF,Bruno T,Delpino A,Iacobini C,Benassi M

    更新日期:1992-08-01 00:00:00

  • Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study.

    abstract::Magnesium wasting is a frequent side effect of epidermal growth factor receptor (EGFR)-antibody treatment as magnesium-absorption mechanisms are dependent on EGFR signaling. EGFR-inhibition results in decreased renal reabsorption. There is evidence that hypomagnesemia during cetuximab treatment correlates with respons...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000965

    authors: Schulz C,Heinemann V,Heinrich K,Haas M,Holch JW,Fraccaroli A,Held S,von Einem JC,Modest DP,Fischer von Weikersthal L,Kullmann F,Moehler M,Scheithauer W,Jung A,Stintzing S

    更新日期:2020-09-01 00:00:00

  • Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine.

    abstract::The aim of this study was to evaluate the effect of coadministration of acid-reducing agents on the pharmacokinetic exposure of orally administered epidermal growth factor receptor inhibitor erlotinib, a drug that displays pH-dependent solubility. Two studies were conducted, the first with the proton pump inhibitor om...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/CAD.0000000000000212

    authors: Kletzl H,Giraudon M,Ducray PS,Abt M,Hamilton M,Lum BL

    更新日期:2015-06-01 00:00:00

  • Severe bladder contracture leading to cystectomy after intravesical mitoxantrone chemotherapy.

    abstract::Since the early 1990s, mitoxantrone has been used as a chemotherapeutic agent for adjuvant intravesical treatment following transurethral resection of superficial transitional cell carcinomas of the bladder. Although its efficacy as adjuvant intravesical therapy remains questionable and its use has not gained wide acc...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/cad.0b013e3282f421fe

    authors: Giannakopoulos S,Pantazis T,Kalaitzis C,Antoniou D,Patris E,Touloupidis S

    更新日期:2008-03-01 00:00:00

  • Ascorbic acid-enhanced antiproliferative effect of flavonoids on squamous cell carcinoma in vitro.

    abstract::We examined the effects of flavone and two polyhydroxylated plant flavonoids (quercetin and fisetin), either singly or in combination with ascorbic acid, on the growth of a human squamous cell carcinoma cell line (HTB 43) in vitro. Fisetin and quercetin significantly impaired cell growth in the presence of ascorbic ac...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199302000-00012

    authors: Kandaswami C,Perkins E,Soloniuk DS,Drzewiecki G,Middleton E Jr

    更新日期:1993-02-01 00:00:00

  • Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines.

    abstract::The cytotoxic activity of bendamustine hydrochloride was evaluated against human ovarian and breast carcinoma cell lines including cell lines resistant to cisplatin and doxorubicin in vitro. The relative degree of resistance to bendamustine hydrochloride was lower in all cell lines compared with cyclophosphamide, melp...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199606000-00007

    authors: Strumberg D,Harstrick A,Doll K,Hoffmann B,Seeber S

    更新日期:1996-06-01 00:00:00

  • In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by novel traditional Chinese medicine-platinum anti-cancer agents.

    abstract::Protein phosphatase 2A (PP2A) is a new target for platinum (Pt)-based cancer chemotherapeutic agents. A series of novel Pt complexes containing demethylcantharidin, a modified component of a traditional Chinese medicine (TCM), [Pt(C8H8O5)(NH2R)2] 1-5 have been shown to inhibit PP2A both in its purified form and in cel...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/01.cad.0000175586.31940.50

    authors: To KK,Ho YP,Au-Yeung SC

    更新日期:2005-09-01 00:00:00

  • Chitosan nanoparticles for dermaseptin peptide delivery toward tumor cells in vitro.

    abstract::The present study aimed to entrap and characterize the morphology and antitumor effects of a dermaseptin (DStomo01) peptide in chitosan nanoparticles, in vitro. DStomo01 nanoparticles showed moderate polydispersivity, excellent colloidal stability, and slow release. It was noted that free DStomo01 induced DNA fragment...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000052

    authors: Medeiros KA,Joanitti GA,Silva LP

    更新日期:2014-03-01 00:00:00

  • Liver X receptor as a drug target for the treatment of breast cancer.

    abstract::Liver X receptor (LXR) has been exploited widely as a drug target in breast cancer treatment, and various mechanisms underlying the effects of LXR in this area are well studied. The activated LXR plays important roles in estrogen receptor α (ERα) breast cancer cells, such as reducing cell proliferation and arresting c...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/CAD.0000000000000348

    authors: Wu Y,Yu DD,Yan DL,Hu Y,Chen D,Liu Y,Zhang HD,Yu SR,Cao HX,Feng JF

    更新日期:2016-06-01 00:00:00

  • Successful treatment with personalized dosage of imatinib in elderly patients with gastrointestinal stromal tumors.

    abstract::Imatinib is the standard first-line therapy for metastatic gastrointestinal stromal tumors. It has markedly improved the prognosis and outcome of patients affected by gastrointestinal stromal tumors, especially in the case of exon 11 KIT mutations. Imatinib-associated adverse events are generally mild to moderate; how...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000331

    authors: Saponara M,Gatto L,Di Nunno V,Tabacchi E,Fanti S,Di Scioscio V,Nannini M,Gruppioni E,Altimari A,Fiorentino M,Santini D,Ceccarelli C,Zompatori M,Biasco G,Pantaleo MA

    更新日期:2016-04-01 00:00:00

  • Inhibition of NADPH oxidase protects against metastasis of human lung cancer by decreasing microRNA-21.

    abstract::The objective of this study was to detect the effect of NADPH oxidase (NOX) inhibition on metastasis of lung cancer. Primary human lung cancer cells were isolated from surgical tissues using the Cancer Cell Isolation Kit. Invasion was detected using the BD Biocoat Matrigel Invasion Chamber assay. Expressions of microR...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000198

    authors: Yan S,Liu G,Pei C,Chen W,Li P,Wang Q,Jin X,Zhu J,Wang M,Liu X

    更新日期:2015-04-01 00:00:00

  • DNA topoisomerase-targeting antitumor agents and drug resistance.

    abstract::A review of the chemotherapeutic agents which have been developed by targeting DNA topoisomerase I and II is presented. Camptothecins as topoisomerase I-targeting agents and newly developed topoisomerase II-targeting agents with unique properties are expected to be promising anticancer agents in the near future. An im...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/00001813-199208000-00002

    authors: Takano H,Kohno K,Matsuo K,Matsuda T,Kuwano M

    更新日期:1992-08-01 00:00:00

  • Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy.

    abstract::The role of pazopanib in the second-line setting of refractory metastatic transitional cell carcinoma of the urothelium has not been defined clearly. The aim of this phase I/II trial was to assess the safety, tolerability, and efficacy of combining pazopanib and vinflunine in patients with metastatic transitional cell...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e32835efe78

    authors: Gerullis H,Eimer C,Ecke TH,Georgas E,Arndt C,Otto T

    更新日期:2013-04-01 00:00:00

  • Inhibition of breast tumor growth in mice after treatment with ceramide analog 315.

    abstract::The aim of this study was to evaluate the anticancer and antitumor activities of ceramide analog 315 in nude mice. Nude mice (n=10) were injected bilaterally with 5×10 MDA-MB-231 cells on each side. Tumors were allowed to form for 2 weeks. The mice were then divided into two groups (n=5 in each group). The control gro...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000675

    authors: Ponnapakkam T,Saulsberry T,Hill T,Hill-Odom M,Goyal N,Anbalagan M,Liu J,Foroozesh M

    更新日期:2018-10-01 00:00:00

  • No pharmacokinetic drug-drug interaction between nevirapine and paclitaxel.

    abstract::We have investigated the pharmacokinetics of nevirapine and paclitaxel in a patient who used both drugs concomitantly, as there are strong theoretical indications for a potential pharmacokinetic drug-drug interaction. Plasma concentrations of nevirapine (dose: 200 mg twice daily orally) and paclitaxel (dose: 100 mg/m(...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200507000-00006

    authors: Kappelhoff BS,Huitema AD,Mairuhu AT,Schellens JH,Beijnen JH

    更新日期:2005-07-01 00:00:00